Inflammatory bowel disease: clinical aspects and established and evolving therapies - PubMed (original) (raw)

Review

Inflammatory bowel disease: clinical aspects and established and evolving therapies

Daniel C Baumgart et al. Lancet. 2007.

Abstract

Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders. In this paper we discuss the current diagnostic approach, their pathology, natural course, and common complications, the assessment of disease activity, extraintestinal manifestations, and medical and surgical management, and provide diagnostic and therapeutic algorithms. We critically review the evidence for established (5-aminosalicylic acid compounds, corticosteroids, immunomodulators, calcineurin inhibitors) and emerging novel therapies--including biological therapies--directed at cytokines (eg, infliximab, adalimumab, certolizumab pegol) and receptors (eg, visilizumab, abatacept) involved in T-cell activation, selective adhesion molecule blockers (eg, natalizumab, MLN-02, alicaforsen), anti-inflammatory cytokines (eg, interleukin 10), modulation of the intestinal flora (eg, antibiotics, prebiotics, probiotics), leucocyte apheresis and many more monoclonal antibodies, small molecules, recombinant growth factors, and MAP kinase inhibitors targeting various inflammatory cells and pathways. Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects.

PubMed Disclaimer

Comment in

Inflammatory bowel disease.
Stocco G, Decorti G, Bartoli F, Martelossi S, Ventura A. Stocco G, et al. Lancet. 2007 Jul 28;370(9584):316-7. doi: 10.1016/S0140-6736(07)61155-6. Lancet. 2007. PMID: 17662875 No abstract available.
Inflammatory bowel disease.
Augoustides JG. Augoustides JG. Lancet. 2007 Jul 28;370(9584):317. doi: 10.1016/S0140-6736(07)61156-8. Lancet. 2007. PMID: 17662878 No abstract available.

Cited by

Research progress of probiotics and their protective strategy in the field of inflammatory bowel disease treatment: A review.
Xiong M, Sun W. Xiong M, et al. Medicine (Baltimore). 2024 Nov 1;103(44):e40401. doi: 10.1097/MD.0000000000040401. Medicine (Baltimore). 2024. PMID: 39495980 Free PMC article. Review.
Prevalence of depression and anxiety in people with inflammatory bowel disease and associated healthcare use: population-based cohort study.
Irving P, Barrett K, Nijher M, de Lusignan S. Irving P, et al. Evid Based Ment Health. 2021 Mar 30;24(3):102-9. doi: 10.1136/ebmental-2020-300223. Online ahead of print. Evid Based Ment Health. 2021. PMID: 33785498 Free PMC article.
Inflammatory Bowel Disease and Cardiovascular Disease: An Integrative Review With a Focus on the Gut Microbiome.
Sanchez Cruz C, Rojas Huerta A, Lima Barrientos J, Rodriguez C, Devani A, Boosahda V, Rasagna Mareddy NS, Briceno Silva G, Del Castillo Miranda JC, Reyes Gochi KA, Reyes Gochi MD, Alvarez S, Ghattas Hasbun PE. Sanchez Cruz C, et al. Cureus. 2024 Jul 22;16(7):e65136. doi: 10.7759/cureus.65136. eCollection 2024 Jul. Cureus. 2024. PMID: 39170992 Free PMC article. Review.
N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors.
Bernabucci M, Notartomaso S, Zappulla C, Fazio F, Cannella M, Motolese M, Battaglia G, Bruno V, Gradini R, Nicoletti F. Bernabucci M, et al. Mol Pain. 2012 Oct 23;8:77. doi: 10.1186/1744-8069-8-77. Mol Pain. 2012. PMID: 23088864 Free PMC article.
Protective effects of ethanol extract from Portulaca oleracea L on dextran sulphate sodium-induced mice ulcerative colitis involving anti-inflammatory and antioxidant.
Yang X, Yan Y, Li J, Tang Z, Sun J, Zhang H, Hao S, Wen A, Liu L. Yang X, et al. Am J Transl Res. 2016 May 15;8(5):2138-48. eCollection 2016. Am J Transl Res. 2016. PMID: 27347321 Free PMC article.

Inflammatory bowel disease: clinical aspects and established and evolving therapies - PubMed (original) (raw)